Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 10/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.78 |
| ▸ | POLB | P06746 | 2/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 8/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.57 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL189608 | 0.88 | ALDH1A1 (1.00) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL189044 | 0.88 | RXFP1 (1.00) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL21313680 | 0.86 | RXFP1 (0.74) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL2302031 | 0.85 | ALDH1A1 (0.78) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL2300231 | 0.85 | RXFP1 (1.00) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL2306135 | 0.85 | ALDH1A1 (0.78) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL3576814 | 0.85 | ALDH1A1 (0.78) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL2301679 | 0.85 | RXFP1 (0.83) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL10044530 | 0.85 | RXFP1 (0.73) | RXFP1KDM4EALDH1A1POLBNPSR1 | |
| SCHEMBL2302089 | 0.85 | RXFP1 (0.73) | RXFP1KDM4EALDH1A1POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | claimed |
| CN-101663283-B | Quinoxaline compounds and use thereof | MERCK SERONO SA | 2014-04-09 | — | — | CN | claimed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | claimed |
| CN-101663283-A | Quinoxaline compounds and use thereof | MERCK SERONO SA | 2010-03-03 | — | — | CN | claimed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8877757-B2 | Pyrazine derivatives and use as PI3K inhibitors | MERCK SERONO SA (CH) | 2014-11-04 | — | — | US | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2630130-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | Merck Serono S.A. Geneva (CH) | 2013-08-28 | — | — | EP | disclosed |
| CN-103270027-A | Process for preparing substituted N- (3-amino-quinoxalin-2-yl) -sulfonamides and their intermediates N- (3-chloro-quinoxalin-2-yl) -sulfonamides | MERCK SERONO S A GENEVA | 2013-08-28 | — | — | CN | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | MERCK SERONO SA (CH) | 2009-03-26 | — | — | US | disclosed |
| CN-101296909-A | Pyrazine derivatives and application thereof as PI3K inhibitor | SERONO LAB (CH) | 2008-10-29 | — | — | CN | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
| EP-1917252-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007023186-A1 | PYRAZINE DERIVATIVES AND USE AS PI3K INHIBITORS | LABORATOIRES SERONO S.A. (CH) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | RXFP1 1332/4885KDM4E 2803/4885ALDH1A1 577/4885 |
| US-20090082356-A1 | Pyrazine Derivatives and Use as P13k Inhibitors | PI4KA, PIP5K1B, PDPK1 | RXFP1 4100/4885KDM4E 2673/4885ALDH1A1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.